HYPERDRIVE
SCIENCE
OUR TECHNOLOGY
01 / FAST
In protein target identification, information on potential targets is normally returned in two weeks given a molecule of interest.
02 / VERSATILE
Multiple libraries from various cell models can be screened concurrently to extract maximal information on the potential binding partners for a molecule of interest.
03 / EASY
A one-stop shop for protein target identification without the need to have any prior information on the potential mode-of-action of a given molecule of interest.
News
2019 Hyperdrive Science awarded New South Wales Minimal Viable Product grant
​
2018 Watch Hyperdrive Science at DEMO NIGHT! Winner of the People's Choice Award for Highest Impact. Live streaming here
https://www.streamgate.co/csiro-on-accelerate4/
CSIRO press release: https://www.csiro.au/en/News/News-releases/2018/ON-demo-night-winners
CSIRO annual awards recognise innovative sci-tech ideas
http://www.manmonthly.com.au/news/csiro-annual-awards-recognise-innovative-sci-tech-ideas/
2018 Congratulations to the top 10 for CSIRO ON Accelerate4
2018 Macquarie University Congratulates our Hyperdrive team for CSIRO ON Accelerate4 program
2017 Hyperdrive makes the top 20 teams for CSIRO ON Acccelerate4 bootcamp
​
​
​
​
CONTACT US
Please fill your contact details below:
Hyperdrive Science
9 Research Park Drive
Macquarie University
NSW 2113
AUSTRALIA
​
e: peter.karuso@hyperdrivescience.com
MEET HYPERDRIVE
OUR STORY
We are a group of scientists and entrepreneurs from Macquarie University that have joined forces to find a new approach to solving problems in the drug discovery and development area.
OUR VISION
We believe that it is possible to improve the current drug discovery process to reduce the cost of health care and increase patient benefits.
OUR TECHNOLOGY
Our technology allows a highly parallel approach to finding potential targets of drug candidates and enables more informed decisions in drug discovery.
OUR TEAM
Dr Fei Liu CBO/CMO
​
PhD in Chemistry (Yale), postdoc (Harvard) and expert in synthetic chemistry, biosynthesis, chemical proteomics, and network pharmacology
Prof Peter Karuso CEO
​
PhD in Chemistry (USyd), postdoc (Texas A&M, TUM) and expert in drug discovery, natural products chemistry and phage display. Developed the concept of “reverse chemical proteomics”
Dr Paul Jaschke CTO
​
PhD in Molecular Biology (UBC), Postdoc (Stanford) and expert in synthetic biology, gene technology, and phage engineering